Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01093 CSPC PHARMA
RTNominal up6.220 +0.170 (+2.810%)
Others

12/02/2018 09:29

CSPC Pharma (01093) breast cancer drug granted approval

[ET Net News Agency, 12 February 2018] CSPC Pharmaceutical (01093) said the "Paclitaxel
for Injection (albumin-bound)" developed by the Group has been granted drug registration
approval by the China Food and Drug Administration of the People's Republic of China.
Paclitaxel for injection (albumin-bound) is an antimicrotubule agent indicated for the
treatment of metastatic breast cancer after failure of combination chemotherapy or breast
cancer relapse within 6 months of adjuvant chemotherapy. The drug has already been
launched in around 27 countries. (HL)

Back to Others

Remark: Real time quote last updated: 24/04/2024 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.